
This study provides critical multi-omics evidence for the precise stratification of multiple myeloma, directly guiding the construction strategies of preclinical disease models to simulate drug resistance mechanisms across different molecular subtypes.
Literature Overview
This article, titled "Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy," published in Nature Medicine, systematically explores the deep associations between genomic, transcriptomic, and epigenomic features and minimal residual disease (MRD) status in newly diagnosed multiple myeloma patients under standardized quadruplet induction therapy.Background Knowledge
Although the quadruplet regimen consisting of CD38 antibodies, proteasome inhibitors, immunomodulators, and dexamethasone has become the standard of care for newly diagnosed multiple myeloma, there is significant heterogeneity in treatment response among patients, and reliable molecular biomarkers to guide early therapeutic decisions are lacking. The main pain point in current multiple myeloma research lies in accurately predicting which patients will fail to achieve MRD-negative status, thereby avoiding ineffective treatment. Traditional single-omics analyses struggle to comprehensively解析 the synergistic effects of driver genes such as MYC and CCND1 within the context of complex genomic instability. This study integrates whole-genome sequencing, RNA sequencing, and whole-genome enzymatic methylation sequencing data to reveal how the B-cell differentiation state, proliferation programs, and specific genomic instability phenotypes (such as APOBEC mutagenesis, chromothripsis, and BRCA2 loss) collectively determine treatment outcomes, offering a new molecular perspective to overcome the drug resistance bottleneck in multiple myeloma.
Research Methods and Core Experiments
Based on the MIDAS clinical trial cohort, the authors conducted a multi-omics integrated analysis of 423 newly diagnosed multiple myeloma samples, including whole-genome sequencing (WGS), RNA sequencing (RNA-seq), and whole-genome enzymatic methylation sequencing (WGEM-seq). The study first defined eight gene expression subgroups through unsupervised clustering and correlated them with specific chromosomal translocations and ploidy characteristics. Key evidence showed that the HP1/HP3 and MS subgroups exhibited higher MRD-negative rates after induction therapy, whereas the CD2 and MF subgroups responded poorly. Furthermore, through differential expression analysis, the study identified B-cell differentiation gene programs (such as PAX5) associated with MRD positivity, and MYC and proliferation programs associated with MRD negativity. Additionally, whole-genome sequencing revealed new genomic instability phenotypes, including mismatch repair defects driven by MSH2 mutations and focal deletion signatures associated with BRCA2 inactivation. These findings were validated transcriptomically in the CASSIOPEIA cohort and confirmed the fusion activation events of novel driver genes IRAK1 and FOXR1 in the MMRF cohort.Key Conclusions and Perspectives
Research Significance and Prospects
These findings offer significant guidance for drug development, particularly in developing targeted therapeutic strategies against novel drivers such as IRAK1 and FOXR1. In terms of clinical monitoring, multi-omics features can serve as more sensitive early predictive biomarkers than traditional clinical indicators, helping physicians identify high-risk patients early during induction therapy and adjust regimens accordingly. Furthermore, the genomic instability phenotypes revealed (such as BRCA2 loss) provide a theoretical basis for utilizing synthetic lethality strategies, such as PARP inhibitors, to treat specific subtypes of multiple myeloma. For disease modeling, these molecular features provide precise gene editing targets for constructing multiple myeloma animal models that better reflect clinical heterogeneity.
Conclusion
Through large-scale multi-omics integrated analysis, this study established a molecular classification system tightly linked to quadruplet combination therapy response in newly diagnosed multiple myeloma patients for the first time. The study not only clarified that B-cell differentiation status and proliferation programs are key biological factors determining MRD clearance but also revealed the roles of genomic instability features such as MSH2 and BRCA2, as well as novel driver genes like IRAK1 and FOXR1, in disease progression. These findings break the limitations of traditional single-dimension stratification, providing a solid molecular foundation for precision medicine in multiple myeloma. From laboratory to clinical translation, this study suggests that future therapeutic strategies should be dynamically adjusted based on patients' multi-omics profiles, particularly developing specific interventions for subtypes with high proliferation, low differentiation, or specific genomic defects. This will significantly enhance the early prediction of therapeutic efficacy in multiple myeloma, optimize treatment pathways, and ultimately improve long-term survival outcomes, becoming a cornerstone of future care systems for related diseases.

